REGENXBIO reported strong second-quarter results, announcing the initiation of RGX-202 BLA filing and up to ~2H 2027 catalyst expectations, extending its cash runway consistent with its gene therapy pipeline development progress.
REGENXBIO reported strong second-quarter results, announcing the initiation of RGX-202 BLA filing and up to ~2H 2027 catalyst expectations, extending its cash runway consistent with its gene therapy pipeline development progress.